Is the price fair?
What KNSA's price assumes
Kiniksa Pharmaceuticals International, plc trades at 84.8× earnings against 24.3× for the median Drug Manufacturers - Specialty & Generic name, more expensive than its own group.
84.8
Trailing P/E · Drug Manufacturers - Specialty & Generic median 24.3 · 3.50× the median: the market pays up for this one
- Price / sales
- 5.26
Price / sales · as of 2026-Q1
- Free cash flow yield
- 3.8%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.4%
- Growth the price implies
- +9.4%
Growth the price implies · The price pays for +9.4% free cash flow growth a year for a decade; the business has delivered +1463% a year over the last three.
Details›
- Price / book2026-Q1
- 6.55
- Healthcare median P/E362 names
- 29.9
- Drug Manufacturers - Specialty & Generic median P/E32 names
- 24.3
- Free cash flow, trailing twelve months
- $164M
- Market capitalisation
- $4.38B
- 3-year revenue growth
- +47%
- 3-year free cash flow growth
- +1463%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - Specialty & Generic
Ranks #10 of 29 by Smart Score